Nine Chapters Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Nine Chapters Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$362K	Buy	32,300 +18,700	+138%	+$206K	0.8%	49
2017 Q2	$150K	Sell	13,600 -27,100	-67%	-$271K	1.42%	37
2017 Q1	$399K	Buy	+40,700	New	+$406K	0.54%	67
2016 Q4	–	Sell	-15,400	Closed	-$158K	–	200
2016 Q3	$158K	Buy	+15,400	New	+$168K	1.11%	42
2015 Q4	–	Sell	-127,800	Closed	-$887K	–	814
2015 Q3	$887K	Sell	127,800 -13,800	-10%	-$118K	0.08%	377
2015 Q2	$1.39M	Buy	141,600 +33,700	+31%	+$307K	0.12%	254
2015 Q1	$956K	Buy	107,900 +40,800	+61%	+$325K	0.08%	386
2014 Q4	$588K	Buy	67,100 +42,900	+177%	+$347K	0.05%	487
2014 Q3	$167K	Buy	24,200 +12,700	+110%	+$76.1K	0.01%	877
2014 Q2	$60K	Buy	+11,500	New	+$56K	﹤0.01%	903
2013 Q4	–	Sell	-10,300	Closed	-$52K	–	1019
2013 Q3	$52K	Buy	+10,300	New	+$57.4K	0.01%	715

Other funds holding SCLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nine Chapters Capital Management's SCLN Position: Q3 2017 in Review

Nine Chapters Capital Management increased its Sciclone Pharmaceuticals Inc (SCLN) stake by 138% in Q3 2017, buying an estimated $206K and bringing the position to 32,300 shares worth $362K. The position accounts for 0.8% of the portfolio, ranked #49.

Nine Chapters Capital Management first reported a position in SCLN in Q3 2013 and has held it in 11 quarters since. The position peaked at $1.39M in Q2 2015. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

Nine Chapters Capital Management held 32,300 shares of Sciclone Pharmaceuticals Inc worth $362K as of Q3 2017.
Nine Chapters Capital Management bought 18,700 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $206K.
Sciclone Pharmaceuticals Inc made up 0.8% of Nine Chapters Capital Management's portfolio in Q3 2017, its #49 holding.
Nine Chapters Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q3 2013 and has held it in 11 quarters since.
Nine Chapters Capital Management's Sciclone Pharmaceuticals Inc position peaked at $1.39M in Q2 2015.
129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Nine Chapters Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.